Adia Med Moves to Cancel 30.78% of Its Own Shares as Invalidly Issued
ADIA has more than doubled off its 52-week low of $0.023 on light trading volume (0.1× avg).
Summary
Adia Med filed a declaratory judgment action to cancel 29.06 million shares (30.78% of outstanding) it claims were never validly issued or paid for. A win would shrink the share count by nearly a third; a loss leaves the shares outstanding and opens the door to counterclaims.
Key Events · Legal and Risk Events · ADIA
-
Lawsuit Seeks to Cancel 29.06M Shares
Adia Med filed a declaratory judgment action in Seminole County, Florida to quiet title in 29,059,792 shares of common stock, which it alleges represent 30.78% of issued and outstanding shares.
-
Shares Valued at $3.49M
The disputed shares had a market value of $3,487,175.04 based on the August 13, 2026 closing price, according to the complaint.
-
Alleged Invalid Issuance
The company claims the 13 named claimants never paid for the shares and that the transfer agent has no record of original issuance; their positions rest solely on the stock transfer ledger.
-
Potential Share Count Reduction
A judgment quieting title in the company would reduce outstanding shares by up to 29,059,792, but the company has not cancelled the shares and will not treat them as retired absent a court order and transfer agent action.
Analysis · ADIA · Life Sciences
A Florida court is being asked to declare that 29.06 million shares—nearly a third of Adia Med's outstanding common stock—were never validly issued and should be cancelled. The company alleges the 13 named claimants never paid for the shares and that the transfer agent has no record of original issuance. A win would shrink the share count by up to 30.78%, mechanically boosting per-share value for remaining holders. A loss would leave the shares outstanding and expose the company to potential counterclaims. The dispute traces back to a January 2024 change of control, when Legends Investment Properties acquired the Series A preferred stock carrying 60% voting rights and the company says it discovered the shareholder list included positions with no supporting issuance records. No hearing has been set and no defendant has responded, so the outcome is uncertain and legal costs are unknown.
How filings like this one have moved
In the 30 days to Oct 22, 2026, 36.9% of the 1029 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.77%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, ADIA was trading at $0.10 on OTC in the Life Sciences sector, with a market capitalization of approximately $9.5M. The 52-week trading range was $0.02 to $0.28. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.